source
- Biotech firms raise record funds in 2026, with $2.1 bn round for Isomorphic LabsAfter a few slow years, the biotech financing landscape is showing signs of recovery, though investors remain cautious about where they place capital. A recent PharmaVoice reader poll found that 2…
- Theravance, after clinical setbacks, agrees to $929M buyoutThe acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a type of low blood pressure.BioPharma Dive · 1mo ago↗ source